Literature DB >> 30946159

Associations between lipids and subclinical coronary atherosclerosis.

Seamus P Whelton1, Jennifer A Deal2, Michelle Zikusoka3, Lisa P Jacobson2, Sudipa Sarkar4, Frank J Palella5, Lawrence Kingsley6, Matthew Budoff7, Mallory D Witt8, Todd T Brown4, Wendy S Post1,2.   

Abstract

OBJECTIVE: Whether HIV modifies the relationship of serum lipids with coronary atherosclerosis and coronary plaque subtypes is uncertain. We examined the associations between traditional lipids and coronary atherosclerosis among HIV-infected (HIV+) and HIV-uninfected (HIV-) men.
DESIGN: The Multicenter AIDS Cohort Study is an observational cohort with a total of 429 HIV+ and 303 HIV- men who had non-contrast cardiac computed tomography performed to measure coronary artery calcium and coronary computed tomography angiography to measure coronary stenosis, coronary plaque presence, and composition.
METHODS: We used multivariable adjusted prevalence ratios to examine the relationship between the SD difference in each lipid parameter and coronary atherosclerosis.
RESULTS: Total cholesterol (TC)/HDL-cholesterol had the strongest associations with coronary atherosclerosis regardless of HIV status. Overall, lipid parameters were most strongly associated with the presence of mixed plaque, stenosis more than 50%, and coronary artery calcium for both HIV+ and HIV- men. HIV+ men had similar, but weaker associations, between lipid parameters and coronary atherosclerosis compared with HIV- men. The strongest association was between the TC/HDL-cholesterol and stenosis more than 50% for both HIV+ [prevalence ratios 1.25 per SD (95% confidence interval 1.07-1.43)] and HIV- men [prevalence ratios 1.46 per SD (95% confidence interval 1.08-1.85)].
CONCLUSION: The associations between lipids and coronary atherosclerosis tended to be weaker for HIV+ compared with HIV- men, although TC/HDL had the strongest association for both HIV+ and HIV- men. A weaker association between lipid levels and coronary atherosclerosis for HIV+ men may contribute to the decreased discrimination of cardiovascular disease risk observed in HIV+ individuals.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30946159      PMCID: PMC6457132          DOI: 10.1097/QAD.0000000000002151

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  33 in total

1.  2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Authors:  David C Goff; Donald M Lloyd-Jones; Glen Bennett; Sean Coady; Ralph B D'Agostino; Raymond Gibbons; Philip Greenland; Daniel T Lackland; Daniel Levy; Christopher J O'Donnell; Jennifer G Robinson; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Paul Sorlie; Neil J Stone; Peter W F Wilson; Harmon S Jordan; Lev Nevo; Janusz Wnek; Jeffrey L Anderson; Jonathan L Halperin; Nancy M Albert; Biykem Bozkurt; Ralph G Brindis; Lesley H Curtis; David DeMets; Judith S Hochman; Richard J Kovacs; E Magnus Ohman; Susan J Pressler; Frank W Sellke; Win-Kuang Shen; Sidney C Smith; Gordon F Tomaselli
Journal:  Circulation       Date:  2013-11-12       Impact factor: 29.690

2.  A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol.

Authors:  G R Warnick; J J Albers
Journal:  J Lipid Res       Date:  1978-01       Impact factor: 5.922

3.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

4.  Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy.

Authors:  G J Moyle; M Lloyd; B Reynolds; C Baldwin; S Mandalia; B G Gazzard
Journal:  AIDS       Date:  2001-08-17       Impact factor: 4.177

5.  Associations between antiretroviral use and subclinical coronary atherosclerosis.

Authors:  Guajira P Thomas; Xiuhong Li; Wendy S Post; Lisa P Jacobson; Mallory D Witt; Todd T Brown; Lawrence A Kingsley; John P Phair; Frank J Palella
Journal:  AIDS       Date:  2016-10-23       Impact factor: 4.177

6.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.

Authors: 
Journal:  N Engl J Med       Date:  1998-11-05       Impact factor: 91.245

7.  Use of cardiac CT angiography imaging in an epidemiology study - the Methodology of the Multicenter AIDS Cohort Study cardiovascular disease substudy.

Authors:  Yalçın Hacıoğlu; Mohit Gupta; Tae Young Choi; Richard T George; Christopher R Deible; Lisa P Jacobson; Mallory D Witt; Frank J Palella; Wendy S Post; Matthew J Budoff
Journal:  Anadolu Kardiyol Derg       Date:  2013-01-30

8.  Lipids and risk of coronary heart disease. The Framingham Study.

Authors:  W P Castelli; K Anderson; P W Wilson; D Levy
Journal:  Ann Epidemiol       Date:  1992 Jan-Mar       Impact factor: 3.797

9.  Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.

Authors:  Nina Friis-Møller; Rainer Weber; Peter Reiss; Rodolphe Thiébaut; Ole Kirk; Antonella d'Arminio Monforte; Christian Pradier; Linda Morfeldt; Silvia Mateu; Matthew Law; Wafaa El-Sadr; Stephan De Wit; Caroline A Sabin; Andrew N Phillips; Jens D Lundgren
Journal:  AIDS       Date:  2003-05-23       Impact factor: 4.177

10.  HIV infection and obesity: where did all the wasting go?

Authors:  Tyler Tate; Amanda L Willig; James H Willig; James L Raper; Linda Moneyham; Mirjam-Colette Kempf; Michael S Saag; Michael J Mugavero
Journal:  Antivir Ther       Date:  2012-09-05
View more
  1 in total

Review 1.  Decoy Technology as a Promising Therapeutic Tool for Atherosclerosis.

Authors:  Maryam Mahjoubin-Tehran; Yong Teng; Amin Jalili; Seyed Hamid Aghaee-Bakhtiari; Alexander M Markin; Amirhossein Sahebkar
Journal:  Int J Mol Sci       Date:  2021-04-23       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.